![]()
|
|
||||||||
J Biol Chem, Vol. 275, Issue 4, 2247-2250, January 28, 2000
From the Department of Medicine, Division of Liver Diseases, Mount Sinai School of Medicine, New York, New York 10029
Encapsulation of injury with fibrosis is a
highly evolved response of adult tissues. In liver, the components of
the process have been greatly clarified, leading to a coherent view of
how wound healing occurs in response to injury. Hepatic fibrogenesis provides an important biological and clinical context for emerging concepts in molecular biochemistry that is relevant to many other tissues.
Chronic injury leading to fibrosis in liver occurs in response to
a variety of insults, including viral hepatitis (especially hepatitis B
and C), alcohol abuse, drugs, metabolic diseases due to overload of
iron or copper, autoimmune attack of hepatocytes or bile duct
epithelium, or congenital abnormalities (1). Typically, injury is
present for months to years before significant scar accumulates,
although the time course may be accelerated in congenital liver
disease. Liver fibrosis is reversible, whereas cirrhosis, the end-stage
consequence of fibrosis, is generally irreversible. Thus, efforts to
understand fibrosis focus primarily on events that lead to the early
accumulation of scar in hopes of identifying therapeutic targets to
slow its progression.
Like other parenchyma, the normal liver contains an epithelial
component (hepatocytes), an endothelial lining (which in liver is
distinguished by fenestrae or pores), tissue macrophages (Kupffer cells), and a perivascular mesenchymal cell called the stellate cell
(previously called Ito cell, lipocyte, perisinusoidal cell, or
fat-storing cell) (Fig. 1); stellate
cells are the key fibrogenic cell (see next section). The cellular
elements of liver are organized within the sinusoid, or microvascular
unit, with the subendothelial space of Disse separating the epithelium
(hepatocytes) from the sinusoidal endothelium. In normal liver this
space contains a basement membrane-like matrix, although it is not
electron-dense like a typical basement membrane. The normal
subendothelial extracellular matrix
(ECM)1 is essential for
maintaining the differentiated function of all resident liver cells.
Establishing the importance of the normal ECM in liver has illuminated
recent attempts to develop artificial liver support by recognizing that
all cellular elements and supporting structures (not just the
hepatocyte compartment) must be reconstituted to preserve
differentiated function of liver ex vivo (2).
![]()
INTRODUCTION
TOP
INTRODUCTION
Background, Disease Context of...
Hepatic Stellate Cells,...
Hepatic Stellate Cell...
Resolution of Liver Fibrosis...
Concluding Remarks
REFERENCES
![]()
Background, Disease Context of Hepatic Fibrosis
TOP
INTRODUCTION
Background, Disease Context of...
Hepatic Stellate Cells,...
Hepatic Stellate Cell...
Resolution of Liver Fibrosis...
Concluding Remarks
REFERENCES

View larger version (84K):
[in a new window]
Fig. 1.
Sinusoidal events during fibrosing liver
injury. Changes in the subendothelial space of Disse and sinusoid
as fibrosis develops in response to liver injury include alterations in
both cellular responses and extracellular matrix composition. Stellate
cell activation leads to accumulation of scar (fibril-forming) matrix.
This in turn contributes to the loss of hepatocyte microvilli and
sinusoidal endothelial fenestrae, which result in deterioration of
hepatic function. Kupffer cell (macrophage) activation accompanies
liver injury and contributes to paracrine activation of stellate
cells.
As the liver becomes fibrotic, there are both quantitative and
qualitative changes in composition of the hepatic ECM. The total
content of collagens and noncollagenous components increases 3-5-fold,
accompanied by the shift in the type of ECM in subendothelial space
from the normal low density basement membrane-like matrix to
interstitial type matrix containing fibril-forming collagens.
| |
Hepatic Stellate Cells, Principal Fibrogenic Cell Type of Liver |
|---|
|
|
|---|
Hepatic stellate cells comprise 15% of the total number of resident liver cells. In normal liver they are the principal storage site for retinoids (3). Stellate cells constitute a heterogeneous group of cells that are functionally and anatomically similar but different in their expression of cytoskeletal filaments, their retinoid content, and their potential for ECM production (4).
Stellate cells have an intriguing embryologic origin, with recent
evidence suggesting that they are neural crest-derived because they
express glial fibrillary acidic protein and nestin (Ref. 5 and
references therein). A neural crest origin is further supported by
studies in rat neural crest stem cells, which differentiate into
myofibroblasts that express smooth muscle
-actin (6), a marker of
activated stellate cells. These observations raise the possibility of
using neural crest-specific promoters to drive transgene expression
selectively in stellate cells in vivo and the prospect of
reconstituting stellate cells from a neural crest precursor as part of
efforts to repopulate liver.
The perivascular orientation and long cytoplasmic processes of stellate
cells facilitate their interactions with neighboring cell types. These
processes are adjacent to hepatic nerves, which can respond to
-adrenergic stimulation with an influx of cytosolic calcium and
release of osmolytes (7).
| |
Hepatic Stellate Cell Activation, a Highly Orchestrated Response to Tissue Injury |
|---|
|
|
|---|
Following liver injury of any etiology, hepatic stellate cells undergo a response known as "activation," which is the transition of quiescent cells into proliferative, fibrogenic, and contractile myofibroblasts.
Stellate cell activation is a remarkably pleiotropic yet tightly
programmed response occurring in a reproducible sequence (Fig.
2). The organization of stellate cell
activation into a defined temporal sequence provides a framework in
which cellular events can be placed into a discrete biologic context.
Early events have been termed initiation (also referred to
as the "preinflammatory" stage). Initiation encompasses
rapid changes in gene expression and phenotype that render the cells
responsive to cytokines and other local stimuli. Initiation
is associated with transcriptional events and induction of immediate
early genes. It results from paracrine stimulation due to rapid,
disruptive effects of liver injury on the homeostasis of neighboring
cells and from early changes in ECM composition.
Perpetuation incorporates those cellular events that amplify
the activated phenotype through enhanced cytokine expression and
responsiveness; this component of activation results from autocrine and
paracrine stimulation, as well as from accelerated ECM remodeling.
|
Initiation: Paracrine Stimulation and Transcriptional Events Begin a Cascade of Cellular Responses
Stimuli initiating stellate cell activation derive from injured hepatocytes and neighboring endothelial and Kupffer cells in addition to rapid, subtle changes in ECM composition.
Hepatocytes and Kupffer cells are a potent source of reactive oxygen intermediates (ROI) (8). These compounds exert paracrine stimulation of stellate cells. Moreover, their activity is amplified in vivo by depletion of antioxidants as typically occurs in diseased liver. In cultured stellate cells, conditioned medium from hepatocytes undergoing oxidative stress increases proliferation and collagen synthesis (9). Overexpression in stellate cells of the enzyme cytochrome P4502E1, which generates ROI, stimulates collagen I gene expression; this effect is attenuated by antioxidants (10).
Endothelial cells play a dual role in early stellate cell activation.
Injury to sinusoidal endothelial cells stimulates production of a
splice variant of cellular fibronectin (EIIIA isoform), which has an
activating effect on stellate cells (11). Additionally, endothelial
cells convert latent transforming growth factor-
1 (TGF-
1) to the
active, fibrogenic form through the activation of plasmin (12).
Molecular approaches to explore stellate cell gene regulation during early activation have identified differentially up-regulated genes (13-15). An advantage to the stellate cell system in these studies has been the opportunity to analyze "in vivo" gene expression in freshly purified, homogenous cell isolates. These efforts have yielded a transcription factor (13), an adhesion molecule (ICAM-1) (14), and interestingly, the prion protein (15), among others.
One representative effort to identify regulatory genes during early stellate cell activation has resulted in the cloning of a Kruppel-like factor (KLF) zinc finger gene, Zf9/COPEB/GBF (recently renamed "KLF6"). KLF6 mRNA is rapidly induced in liver injury in vivo and in culture (13) and can transactivate genes regulating ECM accumulation (16). At least two other KLF proteins also regulate stellate cell activation. Sp1, the first member of the KLF family, binds more actively to its consensus motif in activated versus quiescent stellate cells (17, 18). Basic transcription element binding protein 1 (BTEB1) mediates the increase in collagen gene expression, which occurs in response to UV radiation or expression of the transcription factor Jun (19).
Perpetuation: Paracrine and Autocrine Cytokine Activity and ECM Remodeling Sustain the Activated Phenotype
Perpetuation of stellate cell activation involves key phenotypic responses mediated by increased cytokine effects and remodeling of ECM (12). Enhanced cytokine responses occurs through multiple mechanisms (12); among these, increased expression of cell membrane receptors and enhanced signaling are especially important (see Ref. 20 for review). In particular, receptor tyrosine kinases (RTKs), which mediate many of the stellate cell's responses to cytokines, are broadly up-regulated during liver injury (21).
Continued ECM remodeling during this phase underlies virtually all cellular responses characterizing progressive liver injury. The low density subendothelial matrix is progressively replaced by one rich in fibril-forming collagen. This fundamental shift in ECM composition affects the behavior of hepatocytes, sinusoidal endothelium, and stellate cells (Fig. 1).
Fibril-forming ECM also accelerates stellate cell activation. These
effects are mediated not only through interactions with integrins, the
classic ECM receptors, but also through binding to at least one RTK.
Several integrins and their downstream effectors have been identified
in stellate cells, including
1
1,
2
1,
V
1 and
6
4 (20). Recently, a subfamily of
receptor tyrosine kinases, discoidin domain receptors (DDRs), has been
characterized, which unlike other RTKs signal in response to fibrillar
collagens rather than growth factors (22, 23). With the identification of discoidin domain receptor-2 (DDR2) mRNA in stellate cells (21), a mode of matrix-cell interaction in liver has emerged that may explain
why fibril-forming matrix (especially collagen type I) provokes
activation of stellate cells during sinusoidal fibrosis. Thus, as the
subendothelial basement membrane is replaced by fibrillar collagen
stellate cell activation may be perpetuated via binding of collagen to
the DDR2 receptor (21, 22).
Phenotypic Responses of Activated Stellate Cells
Discrete phenotype responses of stellate cells can be identified as their activation in response to liver injury is perpetuated. These include: (a) proliferation; (b) contractility; (c) fibrogenesis; (d) matrix degradation; (e) chemotaxis; (f) retinoid loss; and (g) cytokine release and white blood cell chemoattraction.
Proliferation-- Increased numbers of stellate cells in injured liver arise in part from local proliferation in response to polypeptide growth factors, most of which signal through receptor tyrosine kinases. Platelet-derived growth factor (PDGF) is the best characterized and most potent among these proliferative factors in hepatic fibrosis. Injury is associated with both increased autocrine PDGF and up-regulation of PDGF receptor (20). Activated PDGF receptor recruits the signaling molecule Ras, followed by activation of the ERK/mitogen-activated protein kinase pathway. Additionally, activation of phosphoinositol 3-kinase is necessary for both mitogenesis and chemotaxis by pathways largely independent of ERK activation (24). The proliferative response to PDGF also requires a sustained intake of extracellular (Ca2+) and increased intracellular pH (20). The activities of a PDGF-regulated Na+/H+ (25) and a Na+/Ca+ exchanger (26) both increase in rat stellate cells during activation in culture and in CCl4 liver injury, respectively. This up-regulation is mediated by calcium/calmodulin- and protein kinase C-dependent pathways (25).
Contractility-- Contractility by activated stellate cells represents an important mechanism underlying increased portal resistance during liver injury. The key contractile stimulus toward stellate cells is endothelin-1 (ET-1), which in part is autocrine-derived (27, 28). Up-regulation of ET-1 production is accompanied by increased endothelin-converting enzyme-1, which activates the latent ET-1 (29). ET-1, in addition to its potent contractile effect, also regulates stellate cell proliferation (28, 30).
At least two G-protein-coupled receptors mediate the effects of ET-1. Unlike receptor tyrosine kinases, which are generally induced during activation, ET receptor types A and B are expressed on both quiescent and activated stellate cells (27). However, the relative prevalence of ETA and ETB receptors changes with the cellular activation, and each mediates divergent responses (30). The proliferative effect of ET-1 in quiescent cells correlates with increased Ras/ERK activity, which is blocked with ETA agonists (30). In contrast, the growth inhibitory effect of ET-1 in activated cells is mediated by the ETB receptor (31) via a prostaglandin/cAMP pathway that leads to down-regulation of ERK and c-Jun kinase (JNK) (31).
Fibrogenesis--
TGF-
1 is the dominant stimulus to ECM
production by stellate cells (see Ref. 12 for references therein). A
role for TGF-
1 in perpetuating rather than initiating stellate cell
activation has been established by examining the behavior of stellate
cells in TGF-
1 knockout mice with acute liver injury. These animals have markedly reduced collagen accumulation in response to liver injury
as expected but still have increased smooth muscle
-actin, indicative of stellate cell activation (32).
TGF-
1 is increased in experimental and human hepatic fibrosis. There
are many sources of this cytokine; however, autocrine expression is
most important (see Ref. 33 for review). Transcriptional up-regulation
of the TGF-
1 gene has been demonstrated in culture-activated stellate cells (16). TGF-
1 activity is also enhanced in activated stellate cells through proteolysis of latent TGF-
1 into the active cytokine by a urokinase-type plasminogen activator (12). Release and
activity of TGF-
1 are controlled by a number of intracellular binding proteins (34). A splice variant of latent TGF-
1 binding protein, which lacks a proteinase-sensitive hinge, has been identified in stellate cells (35); this could alter the biologic availability of
TGF-
1 during fibrosis. Enhanced TGF-
1 signaling also underlies the response to injury in stellate cells. Increased binding of TGF-
1
to its signaling (types I and II) receptors occurs, yet type II
receptor mRNA is decreased during stellate cell activation (12,
36).
Up-regulation of collagen synthesis during activation is among the most
striking molecular responses of stellate cells to injury and is
mediated by both transcriptional and post-transcriptional mechanisms,
not all of which can be ascribed to TGF-
1. Transcriptional activation of the type I collagen has been extensively characterized (13, 37, 38). In addition, the half-life of collagen
(I)1 mRNA
increases 20-fold in activated compared with quiescent stellate cells
(39). A conserved stem-loop structure at the 5'-end of the collagen
(I)1 mRNA mediates this enhanced mRNA stability through an
interaction with the 3'-untranslated region (40).
Matrix Degradation-- Changes in matrix protease activity lead to remodeling of the hepatic ECM during liver injury, which both directly and indirectly accelerates stellate cell activation. Stellate cells express virtually all the key components required for matrix degradation (see Refs. 4, 41, and 42 for reviews). In particular they are a key source of matrix metalloproteinase-2 (MMP-2) as well as stromelysin/MMP-3 (41), each of which degrades the normal subendothelial ECM. This degradation of the normal subendothelial ECM hastens its replacement by fibril-forming collagen, which further activates stellate cell growth and MMP-2 production in a positive feedback loop (43, 44). Initial evidence suggests that both of these effects of fibrillar collagen on stellate cells can be mediated by receptor tyrosine kinase DDR2 (45).
Through the up-regulation of tissue inhibitor of metalloproteinase-1 and -2 (TIMP-1 and -2), activated stellate cells can also inhibit the activity of interstitial collagenases, which additionally favors the accumulation of scar (41). Up-regulation of TIMP-1 gene expression requires a high mobility activator protein-1 binding activity, which is absent from quiescent stellate cells; this mode of regulating TIMP-1 gene expression has not previously been described (46).
Stellate Cell Chemotaxis-- The directed migration of activated stellate cells enhances their accumulation in areas of injury. PDGF and monocyte chemotactic protein-1 (MCP-1) have been identified as chemoattractants toward activated but not quiescent stellate cells (24, 47, 48); chemotaxis requires plasminogen activator, presumably to promote matrix degradation as cells advance through ECM (42). Signaling in response to MCP-1 requires phosphoinositol 3-kinase and calcium influx, but unlike in other MCP-1-responsive cell types, its activity in stellate cells is not mediated by the chemokine receptor CCR2, raising the possibility of a novel receptor (47, 49).
Retinoid Loss--
Loss of intracellular vitamin A is a notable
feature of stellate cell activation, yet it remains unknown whether
retinoid loss is required for stellate cells to activate and which
retinoids might accelerate or prevent activation in vivo.
The generation of minor metabolites of retinoic acid (RA), 9-cis RA and
9,13-di-cis RA, has been reported in an experimental model of liver
fibrosis induced by porcine serum administration (50). These compounds may have a direct link to fibrogenesis because they stimulate the
activation of latent TGF-
1, thereby increasing its fibrogenic activity.
Cytokine Release and Leukocyte Chemoattraction-- Increased production and/or activity of cytokines are critical for perpetuation of stellate cell activation. Almost all features of stellate cell activation can be attributed to autocrine cytokines (12). ECM in liver is an important reservoir of bound growth factors (12).
Stellate cells can also amplify inflammation through the release
of neutrophil and monocyte chemoattractants. Key inflammatory chemokines are colony-stimulating factor and MCP-1 (49, 51). The
secretion of MCP-1 is regulated through
1 integrin
stimulation (20). Up-regulation of adhesion molecules accompanying
stellate cell activation further amplifies inflammation during liver
injury (52).
| |
Resolution of Liver Fibrosis and the Fate of Activated Stellate Cells |
|---|
|
|
|---|
During recovery from acute human and experimental liver injury the number of activated stellate cells decreases as tissue integrity is restored. This raises an intriguing question. What happens to activated stellate cells during resolution? Do they revert to quiescent cells or are they cleared? Recently answers have begun to emerge.
Reversion?-- A key unresolved issue is whether an activated stellate cell can revert to a quiescent state. One stimulus that may control this response is interleukin-10 (IL-10). IL-10 down-regulates inflammation and increases interstitial collagenase activity (53, 54). IL-10 is induced during stellate cell activation (53) providing an autocrine negative feedback signal to limit scar accumulation.
In addition to effects of soluble cytokines, regression of stellate cell activation may be possible by reconstitution of the normal subendothelial ECM. When stellate cells are grown on a basement membrane substratum (Matrigel) they remain quiescent (45).
Apoptosis?--
One potential fate of activated stellate
cells is apoptosis (see Ref. 55 for review). Stellate cell apoptosis
associated with reduced TIMP-1 expression has been documented during
the recovery phase of experimentally induced liver injury (56). Stellate cells also undergo apoptosis during spontaneous activation, in
parallel with increased expression of CD95 L (Fas ligand), Bcl-2, and
p53 (55).
| |
Concluding Remarks |
|---|
|
|
|---|
Reductionist models of tissue repair have evolved to clarify
relationships between individual molecules, yet more complex, physiologic systems reveal tremendous redundancy both in whole animals
and culture models. In 3T3 fibroblasts, for example, distinct signaling
pathways mediated by different phosphotyrosines of the
-PDGF
receptor converge on the same set of immediate early genes, albeit to
different extents (57). How then does one identify those signaling
pathways truly relevant to a specific disease? Use of a system
exemplified by hepatic stellate cells, in which cellular behavior is
thoroughly tracked both in vivo and in vitro, provides an important advantage. In stellate cells, gene expression and
protein secretion are regulated not only in a cell-specific manner but
also depend upon the state of cellular activation. Thus, effects of
mediators may diverge at different states of cellular activation,
possibly reflecting recruitment of different pathways in early
versus late liver injury. The stellate cell system,
therefore, provides an ideal platform for large-scale gene analysis
using cDNA or oligonucleotide microarrays or transcriptional profiling, where relevance to behavior in vivo is almost
certain. What is likely to emerge is an even more coherent paradigm for how complex cellular events are integrated to achieve a distinct biologic end point, the encapsulation of tissue injury by scar.
| |
ACKNOWLEDGEMENTS |
|---|
The thoughtful critiques of Drs. J. Maher, F. Ramirez, G. Atweh, and P. Frenette are greatly appreciated. I wish to acknowledge the many outstanding contributions of investigators in the field whose work could not be cited because of space constraints.
| |
FOOTNOTES |
|---|
* This minireview will be reprinted in the 2000 Minireview Compendium, which will be available in December, 2000. My work is supported by National Institutes of Health Grants DK37340 and DK56621, by a grant from the Dean's Office of the Mount Sinai School of Medicine, and by the Artzt Family Foundation.
To whom correspondence should be addressed: Box 1123, Rm. 1170 F,
Mount Sinai School of Medicine, 1425 Madison Ave., New York, NY 10029. Tel.: 212-659-9501; Fax: 212-849-2574; E-mail:
frieds02@doc.mssm.edu.
| |
ABBREVIATIONS |
|---|
The abbreviations used are:
ECM, extracellular
matrix;
ROI, reactive oxygen intermediates;
TGF-
1, transforming
growth factor-
1;
KLF, Kruppel-like factor;
RTK, receptor tyrosine
kinase;
DDR, discoidin domain receptor;
PDGF, platelet-derived growth
factor;
ERK, extracellular signal-regulated kinase;
ET-1, endothelin-1;
MMP, matrix metalloproteinase;
TIMP, tissue inhibitor of
metalloproteinase;
MCP-1, monocyte chemotactic protein-1;
RA, retinoic
acid;
IL-10, interleukin-10.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Friedman, S. L. (1998) in Diseases of the Liver (Schiff, E. , Sorrell, M. , and Maddrey, W., eds), 8th Ed. , pp. 371-386, Lippincott-Raven, Philadelphia |
| 2. | Mitaka, T., Sato, F., Mizuguchi, T., Yokono, T., and Mochizuki, Y. (1999) Hepatology 29, 111-125[CrossRef][Medline] [Order article via Infotrieve] |
| 3. | Wang, X. D. (1999) Nutr. Rev. 57, 51-59[Medline] [Order article via Infotrieve] |
| 4. | Knittel, T., Kobold, D., Saile, B., Grundmann, A., Neubauer, K., Piscaglia, F., and Ramadori, G. (1999) Gastroenterology 117, 1205-1221[CrossRef][Medline] [Order article via Infotrieve] |
| 5. | Niki, T., Pekny, M., Hellemans, K., Bleser, P. D., Berg, K. V., Vaeyens, F., Quartier, E., Schuit, F., and Geerts, A. (1999) Hepatology 29, 520-527[CrossRef][Medline] [Order article via Infotrieve] |
| 6. | Morrison, S. J., White, P. M., Zock, C., and Anderson, D. J. (1999) Cell 96, 737-749[CrossRef][Medline] [Order article via Infotrieve] |
| 7. | vom Dahl, S., Bode, J. G., Reinehr, R. M., Monnighoff, I., Kubitz, R., and Haussinger, D. (1999) Hepatology 29, 195-204[CrossRef][Medline] [Order article via Infotrieve] |
| 8. | Maher, J. J. (1999) Alcohol Clin. Exp. Res. 23, 917-921[Medline] [Order article via Infotrieve] |
| 9. | Svegliati Baroni, G., D'Ambrosio, L., Ferretti, G., Casini, A., Di Sario, A., Salzano, R., Ridolfi, F., Saccomanno, S., Jezequel, A. M., and Benedetti, A. (1998) Hepatology 27, 720-726[CrossRef][Medline] [Order article via Infotrieve] |
| 10. | Nieto, N., Friedman, S. L., Greenwel, P., and Cederbaum, A. (1999) Hepatology 30, 987-996[CrossRef][Medline] [Order article via Infotrieve] |
| 11. |
Jarnagin, W. R.,
Rockey, D. C.,
Koteliansky, V. E.,
Wang, S. S.,
and Bissell, D. M.
(1994)
J. Cell Biol.
127,
2037-2048 |
| 12. | Friedman, S. L. (1999) Semin. Liver Dis. 19, 129-140[Medline] [Order article via Infotrieve] |
| 13. |
Ratziu, V.,
Lalazar, A.,
Wong, L.,
Dang, Q.,
Collins, C.,
Shaulian, E.,
Jensen, S.,
and Friedman, S. L.
(1998)
Proc. Natl. Acad. Sci. U. S. A.
95,
9500-9505 |
| 14. | Hellerbrand, C., Wang, S. C., Tsukamoto, H., Brenner, D. A., and Rippe, R. A. (1996) Hepatology 24, 670-676[CrossRef][Medline] [Order article via Infotrieve] |
| 15. |
Ikeda, K.,
Kawada, N.,
Wang, Y. Q.,
Kadoya, H.,
Nakatani, K.,
Sato, M.,
and Kaneda, K.
(1998)
Am. J. Pathol.
153,
1695-1700 |
| 16. |
Kim, Y.,
Ratziu, V.,
Choi, S. G.,
Lalazar, A.,
Theiss, G.,
Dang, Q.,
Kim, S. J.,
and Friedman, S. L.
(1998)
J. Biol. Chem.
273,
33750-33758 |
| 17. |
Philipsen, S.,
and Suske, G.
(1999)
Nucleic Acids Res.
27,
2991-3000 |
| 18. | Rippe, R. A., Almounajed, G., and Brenner, D. A. (1995) Hepatology 22, 241-251[CrossRef][Medline] [Order article via Infotrieve] |
| 19. |
Chen, A.,
and Davis, B. H.
(1999)
J. Biol. Chem.
274,
158-164 |
| 20. | Pinzani, M., Marra, F., and Carloni, V. (1998) Liver 18, 2-13[Medline] [Order article via Infotrieve] |
| 21. | Ankoma-Sey, V., Matli, M., Chang, K. B., Lalazar, A., Donner, D. B., Wong, L., Warren, R. S., and Friedman, S. L. (1998) Oncogene 17, 115-121[CrossRef][Medline] [Order article via Infotrieve] |
| 22. | Shrivastava, A., Radziejewski, C., Campbell, E., Kovac, L., McGlynn, M., Ryan, T. E., Davis, S., Goldfarb, M., Glass, D. J., Lemke, G., and Yancopoulos, G. D. (1997) Mol. Cell 1, 25-34[CrossRef][Medline] [Order article via Infotrieve] |
| 23. | Vogel, W. (1999) FASEB J. 13 (suppl.), 77-82 |
| 24. | Marra, F., Gentilini, A., Pinzani, M., Choudhury, G. G., Parola, M., Herbst, H., Dianzani, M. U., Laffi, G., Abboud, H. E., and Gentilini, P. (1997) Gastroenterology 112, 1297-1306[CrossRef][Medline] [Order article via Infotrieve] |
| 25. | Di Sario, A., Bendia, E., Svegliati Baroni, G., Ridolfi, F., Bolognini, L., Feliciangeli, G., Jezequel, A. M., Orlandi, F., and Benedetti, A. (1999) Gastroenterology 116, 1155-1166[CrossRef][Medline] [Order article via Infotrieve] |
| 26. |
Nakamura, T.,
Arii, S.,
Monden, K.,
Furutani, M.,
Takeda, Y.,
Imamura, M.,
and Okada, Y.
(1998)
Proc. Natl. Acad. Sci. U. S. A.
95,
5389-5394 |
| 27. | Rockey, D. C. (1997) Hepatology 25, 2-5[CrossRef][Medline] [Order article via Infotrieve] |
| 28. | Rockey, D. C., Fouassier, L., Chung, J. J., Carayon, A., Vallee, P., Rey, C., and Housset, C. (1998) Hepatology 27, 472-480[CrossRef][Medline] [Order article via Infotrieve] |
| 29. |
Shao, R.,
Yan, W.,
and Rockey, D. C.
(1999)
J. Biol. Chem.
274,
3228-3234 |
| 30. | Pinzani, M., Milani, S., De Franco, R., Grappone, C., Caligiuri, A., Gentilini, A., Tosti-Guerra, C., Maggi, M., Failli, P., Ruocco, C., and Gentilini, P. (1996) Gastroenterology 110, 534-548[CrossRef][Medline] [Order article via Infotrieve] |
| 31. | Mallat, A., Preaux, A. M., Serradeil-Le Gal, C., Raufaste, D., Gallois, C., Brenner, D. A., Bradham, C., Maclouf, J., Iourgenko, V., Fouassier, L., Dhumeaux, D., Mavier, P., and Lotersztajn, S. (1996) J. Clin. Invest. 98, 2771-2778[Medline] [Order article via Infotrieve] |
| 32. | Hellerbrand, C., Stefanovic, B., Giordano, F., Burchardt, E. R., and Brenner, D. A. (1999) J. Hepatol. 30, 77-87[CrossRef][Medline] [Order article via Infotrieve] |
| 33. | Gressner, A. M. (1995) J. Hepatol. 22 Suppl. 2, 28-36[CrossRef][Medline] [Order article via Infotrieve] |
| 34. | Gong, W., Gressner, A. M., Michel, K., and Roth, S. (1998) Gastroenterology 114, 352-363[CrossRef][Medline] [Order article via Infotrieve] |
| 35. | Michel, K., Roth, S., Trautwein, C., Gong, W., Flemming, P., and Gressner, A. M. (1998) Hepatology 27, 1592-1599[CrossRef][Medline] [Order article via Infotrieve] |
| 36. | Roulot, D., Sevcsik, A. M., Coste, T., Strosberg, A. D., and Marullo, S. (1999) Hepatology 29, 1730-1738[CrossRef][Medline] [Order article via Infotrieve] |
| 37. |
Brenner, D. A.,
Westwick, J.,
and Breindl, M.
(1993)
Am. J. Physiol.
264,
G589-G595 |
| 38. | Inagaki, Y., Truter, S., Greenwel, P., Rojkind, M., Unoura, M., Kobayashi, K., and Ramirez, F. (1995) Hepatology 22, 573-579[CrossRef][Medline] [Order article via Infotrieve] |
| 39. | Stefanovic, B., Hellerbrand, C., Holcik, M., Briendl, M., Aliebhaber, S., and Brenner, D. A. (1997) Mol. Cell. Biol. 17, 5201-5209[Abstract] |
| 40. |
Stefanovic, B.,
Hellerbrand, C.,
and Brenner, D. A.
(1999)
Mol. Cell. Biol.
19,
4334-4342 |
| 41. | Arthur, M. J. (1995) J. Hepatol. 22 Suppl. 2, 43-48[CrossRef][Medline] [Order article via Infotrieve] |
| 42. | Fibbi, G., Pucci, M., Grappone, C., Pellegrini, G., Salzano, R., Casini, A., Milani, S., and Del Rosso, M. (1999) Hepatology 29, 868-878[CrossRef][Medline] [Order article via Infotrieve] |
| 43. | Theret, N., Lehti, K., Musso, O., and Clement, B. (1999) Hepatology 30, 462-468[CrossRef][Medline] [Order article via Infotrieve] |
| 44. | Benyon, R. C., Hovell, C. J., Da Gaca, M., Jones, E. H., Iredale, J. P., and Arthur, M. J. P. (1999) Hepatology 30, 977-986[CrossRef][Medline] [Order article via Infotrieve] |
| 45. | Olaso, E., Eng, F., Lin, C., Yancopoulos, G., and Friedman, S. L. (1999) Hepatology 30, 413[CrossRef][Medline] [Order article via Infotrieve] (abstr.) |
| 46. | Bahr, M. J., Vincent, K. J., Arthur, M. J., Fowler, A. V., Smart, D. E., Wright, M. C., Clark, I. M., Benyon, R. C., Iredale, J. P., and Mann, D. A. (1999) Hepatology 29, 839-848[CrossRef][Medline] [Order article via Infotrieve] |
| 47. | Marra, F., Romanelli, R. G., Giannini, C., Failli, P., Pastacaldi, S., Arrighi, M. C., Pinzani, M., Laffi, G., Montalto, P., and Gentilini, P. (1999) Hepatology 29, 140-148[CrossRef][Medline] [Order article via Infotrieve] |
| 48. | Ikeda, K., Wakahara, T., Wang, Y. Q., Kadoya, H., Kawada, N., and Kaneda, K. (1999) Hepatology 29, 1760-1767[CrossRef][Medline] [Order article via Infotrieve] |
| 49. | Marra, F., DeFranco, R., Grappone, C., Milani, S., Pastacaldi, S., Pinzani, M., Romanelli, R. G., Laffi, G., and Gentilini, P. (1998) Am. J. Pathol. 152, 423-430[Abstract] |
| 50. | Okuno, M., Sato, T., Kitamoto, T., Imai, S., Kawada, N., Suzuki, Y., Yoshimura, H., Moriwaki, H., Onuki, K., Masushige, S., Muto, Y., Friedman, S. L., Kato, S., and Kojima, S. (1999) J. Hepatol. 30, 1073-1080[CrossRef][Medline] [Order article via Infotrieve] |
| 51. |
Pinzani, M.,
Abboud, H. E.,
Gesualdo, L.,
and Abboud, S. L.
(1992)
Am. J. Physiol.
262,
C876-C881 |
| 52. |
Knittel, T.,
Dinter, C.,
Kobold, D.,
Neubauer, K.,
Mehde, M.,
Eichhorst, S.,
and Ramadori, G.
(1999)
Am. J. Pathol.
154,
153-167 |
| 53. |
Wang, S. C.,
Tsukamoto, H.,
Rippe, R. A.,
Schrum, L.,
and Ohata, M.
(1998)
J. Biol. Chem.
273,
302-308 |
| 54. | Thompson, K. C., Trowern, A., Fowell, A., Marathe, M., Haycock, C., Arthur, M. J. P., and Sheron, N. (1998) Hepatology 28, 1518-1524[CrossRef][Medline] [Order article via Infotrieve] |
| 55. | Gressner, A. M. (1998) Cell Tissue Res. 292, 447-452[CrossRef][Medline] [Order article via Infotrieve] |
| 56. | Iredale, J. P., Benyon, R. C., Pickering, J., McCullen, M., Northrop, M., Pawley, S., Hovell, C., and Arthur, M. J. (1998) J. Clin. Invest. 102, 538-549[Medline] [Order article via Infotrieve] |
| 57. | Fambrough, D., McClure, K., Kazlauskas, A., and Lander, E. S. (1999) Cell 97, 727-741[CrossRef][Medline] [Order article via Infotrieve] |
This article has been cited by other articles:
![]() |
H. Kim, C. J. Booth, A. B. Pinus, P. Chen, A. Lee, M. Qiu, M. Whitlock, P. S. Murphy, and R. T. Constable Induced Hepatic Fibrosis in Rats: Hepatic Steatosis, Macromolecule Content, Perfusion Parameters, and Their Correlations--Preliminary MR Imaging in Rats Radiology, June 1, 2008; 247(3): 696 - 705. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. I. Hagens, L. Beljaars, D.A. Mann, M. C. Wright, B. Julien, S. Lotersztajn, C. Reker-Smit, and K. Poelstra Cellular Targeting of the Apoptosis-Inducing Compound Gliotoxin to Fibrotic Rat Livers J. Pharmacol. Exp. Ther., March 1, 2008; 324(3): 902 - 910. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Miyata, M. Masuya, S. Yoshida, S. Nakamura, K. Kato, Y. Sugimoto, T. Shibasaki, K. Yamamura, K. Ohishi, K. Nishii, et al. Hematopoietic origin of hepatic stellate cells in the adult liver Blood, February 15, 2008; 111(4): 2427 - 2435. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. L. Friedman Hepatic Stellate Cells: Protean, Multifunctional, and Enigmatic Cells of the Liver Physiol Rev, January 1, 2008; 88(1): 125 - 172. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. C. Melton, R. K. Soon Jr., J. G. Park, L. Martinez, G. W. deHart, and H. F. Yee Jr. Focal adhesion disassembly is an essential early event in hepatic stellate cell chemotaxis Am J Physiol Gastrointest Liver Physiol, December 1, 2007; 293(6): G1272 - G1280. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Che, E. S. L. Chan, and B. N. Cronstein Adenosine A2A Receptor Occupancy Stimulates Collagen Expression by Hepatic Stellate Cells via Pathways Involving Protein Kinase A, Src, and Extracellular Signal-Regulated Kinases 1/2 Signaling Cascade or p38 Mitogen-Activated Protein Kinase Signaling Pathway Mol. Pharmacol., December 1, 2007; 72(6): 1626 - 1636. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. A. Mekonnen, J. IJzer, and H. Nederbragt Tenascin-C in Chronic Canine Hepatitis: Immunohistochemical Localization and Correlation with Necro-Inflammatory Activity, Fibrotic Stage, and Expression of Alpha-Smooth Muscle Actin, Cytokeratin 7, and CD3+ Cells Vet. Pathol., November 1, 2007; 44(6): 803 - 813. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Son, Y. Iimuro, E. Seki, T. Hirano, Y. Kaneda, and J. Fujimoto Selective inactivation of NF-{kappa}B in the liver using NF-{kappa}B decoy suppresses CCl4-induced liver injury and fibrosis Am J Physiol Gastrointest Liver Physiol, September 1, 2007; 293(3): G631 - G639. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Safadi, E. Zigmond, O. Pappo, Z. Shalev, and Y. Ilan Amelioration of hepatic fibrosis via beta-glucosylceramide-mediated immune modulation is associated with altered CD8 and NKT lymphocyte distribution Int. Immunol., August 13, 2007; (2007) dxm069v1. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Zeisberg, C. Yang, M. Martino, M. B. Duncan, F. Rieder, H. Tanjore, and R. Kalluri Fibroblasts Derive from Hepatocytes in Liver Fibrosis via Epithelial to Mesenchymal Transition J. Biol. Chem., August 10, 2007; 282(32): 23337 - 23347. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Kaimori, J. Potter, J.-y. Kaimori, C. Wang, E. Mezey, and A. Koteish Transforming Growth Factor-beta1 Induces an Epithelial-to-Mesenchymal Transition State in Mouse Hepatocytes in Vitro J. Biol. Chem., July 27, 2007; 282(30): 22089 - 22101. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. L. Gardner, S. M. Turner, A. Bautista, G. Lindwall, M. Awada, and M. K. Hellerstein Measurement of liver collagen synthesis by heavy water labeling: effects of profibrotic toxicants and antifibrotic interventions Am J Physiol Gastrointest Liver Physiol, June 1, 2007; 292(6): G1695 - G1705. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. BERHE, B. L. HALVORSEN, T. E. GUNDERSEN, B. MYRVANG, S. G. GUNDERSEN, and R. BLOMHOFF REDUCED SERUM CONCENTRATIONS OF RETINOL AND {alpha}-TOCOPHEROL AND HIGH CONCENTRATIONS OF HYDROPEROXIDES ARE ASSOCIATED WITH COMMUNITY LEVELS OF S. MANSONI INFECTION AND SCHISTOSOMAL PERIPORTAL FIBROSIS IN ETHIOPIAN SCHOOL CHILDREN Am J Trop Med Hyg, May 1, 2007; 76(5): 943 - 949. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Kinoshita, Y. Iimuro, K. Otogawa, S. Saika, Y. Inagaki, Y. Nakajima, N. Kawada, J. Fujimoto, S. L Friedman, and K. Ikeda Adenovirus-mediated expression of BMP-7 suppresses the development of liver fibrosis in rats Gut, May 1, 2007; 56(5): 706 - 714. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. F. Si, J. Li, X. W. Lu, and Y. Jin Suppressive Effects of Leflunomide on Leptin-Induced Collagen I Production Involved in Hepatic Stellate Cell Proliferation Experimental Biology and Medicine, March 1, 2007; 232(3): 427 - 436. [Abstract] [Full Text] [PDF] |
||||
![]() |
|